Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2022, Vol. 54 ›› Issue (4): 615-620. doi: 10.19723/j.issn.1671-167X.2022.04.006

Previous Articles     Next Articles

Clinicopathological features and prognostic analysis of papillary renal cell carcinoma

Er-shu BO1,Peng HONG1,Yu ZHANG1,Shao-hui DENG1,Li-yuan GE1,Min LU2,Nan LI3,Lu-lin MA1,Shu-dong ZHANG1,*()   

  1. 1. Department of Urology, Peking University Third Hospital, Beijing 100191, China
    2. Department of Pathology, Peking University Third Hospital, Beijing 100191, China
    3. Research Centre of Clinical Epidemiology, Peking University Third Hospital, Beijing 100191, China
  • Received:2022-04-06 Online:2022-08-18 Published:2022-08-11
  • Contact: Shu-dong ZHANG E-mail:zhangshudong@bjmu.edu.cn
  • Supported by:
    the National Natural Science Foundation of China(82072828);Key Clinical Projects of Peking University Third Hospital(BYSYZD2019016);Innovative Transformation Projects of Haidian District(HDCXZHKC2021208)

RICH HTML

   

PDF (PC)

Abstract:

Objective: To investigate the clinicopathological features and prognostic characteristics of papillary renal cell carcinoma (pRCC). Methods: The clinical data of 114 patients with pRCC, including 91 males and 23 females, admitted to the Department of Urology, Peking University Third Hospital from May 2012 to May 2021 were retrospectively analyzed. All the cases were operated patients with clear pathological diagnosis and complete follow-up data. The log-rank test was used to analyze the relationship between the patients' clinicopathological characteristics and survival time, the Kaplan-Meier method to draw survival curves, and the Cox regression model for univariate and multifactorial analysis. Results: The mean age of the 114 patients was (57.3±12.6) years. The tumors were located in the left kidney in 49 cases and in the right kidney in 65 cases. In the study, 48 radical nephrectomies and 66 partial nephrectomies were performed, 42 cases were type 1 and 72 cases were type 2, and the mean maximum tumor diameter was (5.5±3.6) cm. pT1a stage 52 cases, pT1b stage 22 cases, pT2 stage 4 cases, pT3 stage 33 cases, and pT4 stage 3 cases were staged. According to the World Health Organization / International Society of Urological Pathology (WHO/ISUP), there were 13 cases of gradeⅠ, 44 cases of grade Ⅱ, 51 cases of grade Ⅲ, and 6 cases of grade Ⅳ. And 34 of the 114 patients had vascular cancer embolism, 30 cases had lymph node metastasis, and 3 cases had adrenal metastasis. The median follow-up time after surgery was 22 months, and the 3-year progression-free survival rate was 95.6%. The patients with type 1 and type 2 pRCC showed statistically significant differences in age (P=0.046), body mass index (P=0.008), surgical approach (P=0.001), maximum tumor diameter (P < 0.001), vascular cancer embolism (P < 0.001), lymph node metastasis (P < 0.001), pT stage (P < 0.001), and nuclear grade (P < 0.001). The 3-year progression-free survival rates for type 1 and type 2 pRCC were 100% and 69.4%, respectively, with type 1 having a significantly better prognosis than with type 2 (P=0.003). Univariate analysis of the patients with type 2 pRCC showed that pT stage (P < 0.001), vascular cancer embolism (P < 0.001) and lymph node metastasis (P < 0.001) were strongly associated with their prognosis. Multifactorial analysis showed that vascular cancer embolism was an independent prognostic factor for progression-free survival in type 2 pRCC (P=0.001). Univariate analysis of the pRCC patients undergoing radical nephrectomy showed that pT stage (P=0.006), vascular cancer embolism (P=0.001), and lymph node metastasis (P=0.008) were significant factors affecting their prognosis, and further multifactorial analysis showed that only vascular cancer embolism was an indepen-dent prognostic factor for their progression-free survival (P=0.006). Conclusion: Type 2 pRCC has more morbidity, more lymph node metastases, more advanced pT stage, and higher pathologic grading than type 1 pRCC. The presence of vascular cancer embolism is an independent prognostic factor in patients with type 2 pRCC and pRCC undergoing radical nephrectomy.

Key words: Papillary renal cell carcinoma, Clinical features, Clinical pathology, Prognosis

CLC Number: 

  • R737.11

Table 1

Clinicopathological features of 114 pRCC patients"

Items Value
Gender, n(%)
  Male 91 (79.8)
  Female 23 (20.2)
Age/years, $\bar x \pm s$ 57.3±12.6
BMI/(kg/m2), $\bar x \pm s$ 25.1±3.1
Tumor location, n(%)
  Left 49 (43.0)
  Right 65 (57.0)
Surgical method, n(%)
  Partial nephrectomy 66 (57.9)
  Radical nephrectomy 48 (42.1)
Maximum tumor diameter/cm, $\bar x \pm s$ 5.5±3.6
pT stages, n(%)
  T1a 52 (45.6)
  T1b 22 (19.3)
  T2 4 (3.5)
  T3 33 (28.9)
  T4 3 (2.6)
Nuclear grade, n(%)
  Ⅰ 13 (11.4)
  Ⅱ 44 (38.6)
  Ⅲ 51 (44.7)
  Ⅳ 6 (5.3)
Vascular cancer embolism, n(%)
  Yes 34 (29.8)
  No 80 (70.2)
Adrenal metastasis, n(%)
  Yes 3 (2.6)
  No 111 (97.4)
Lymph node metastasis, n(%)
  Yes 30 (26.3)
  No 84 (73.7)
Symptoms, n(%)
  Osphyalgia 17 (14.9)
  Hematuria 19 (16.7)
  Physical examination found 78 (68.4)

Table 2

Comparison of the clinicopathological features of type 1 and type 2 pRCC"

Items Type 1 Type 2 P
Gender, n 0.231
  Male 36 55
  Female 6 17
Age/years, $\bar x \pm s$ 54.1±11.5 59.0±12.9 0.046
BMI/(kg/m2), $\bar x \pm s$ 26.1±2.9 24.5±3.1 0.008
Tumor location, n 0.421
  Left 16 33
  Right 26 39
Surgical method, n 0.001
  Partial nephrectomy 33 33
  Radical nephrectomy 9 39
Maximum tumor
diameter/cm, $\bar x \pm s$		 3.55±2.30 6.63±3.69 < 0.001
Vascular cancer embolism, n < 0.001
  Yes 1 33
  No 41 39
Lymph node metastasis, n < 0.001
  Yes 0 30
  No 42 42
Adrenal metastasis, n 0.463
  Yes 0 3
  No 42 69
pT stages, n < 0.001
  T1a 28 24
  T1b 10 12
  T2 2 2
  T3 1 32
  T4 1 2
Nuclear grade, n < 0.001
  Ⅰ 13 0
  Ⅱ 24 20
  Ⅲ 5 46
  Ⅳ 0 6
Symptoms, n 0.002
  Osphyalgia 3 14
  Hematuria 2 17
  Physical examination found 37 41

Figure 1

Progression-free survival curves in patients with type 1 and type 2 pRCC after surgery"

Table 3

Univariate and multifactorial analysis of the prognosis associated with type 2 pRCC patients"

Items Univariate analysis Multifactorial analysis
(P)
HR 95%CI P
Gender (Male/Female) 0.296 0.038-2.295 0.215
BMI (>24.9 kg/m2/≤24.9 kg/m2) 0.913 0.290-2.871 0.876
Tumor location (Left/Right) 0.799 0.256-2.498 0.700
Surgical method (Radical/Partial) 3.316 0.886-12.417 0.055 0.100
pT stages (T3-4/ T1-2) 12.495 2.605-59.929 < 0.001 0.584
Nuclear grade (Ⅲ-Ⅳ / Ⅰ-Ⅱ) 1.333 0.391-4.541 0.641
Vascular cancer embolism (Yes/No) 34.301 3.983-295.376 < 0.001 0.001
Lymph node metastasis (Yes/No) 15.257 2.767-84.121 < 0.001 0.558
Adrenal metastasis (Yes/No) 4.009 0.488-32.905 0.274

Figure 2

Progression-free survival curves in patients with type 2 pRCC with and without vascular cancer embolism"

Figure 3

Progression-free survival curves in pRCC patients undergoing partial nephrectomy and radical nephrectomy"

Table 4

Univariate and multifactorial analysis of the prognosis of patients with pRCC after radical nephrectomy"

Items Univariate analysis Multifactorial analysis
(P)
HR 95%CI P
BMI (>24.9/≤24.9 kg/m2) 0.655 0.173-2.477 0.537
Tumor location (Left/Right) 0.984 0.258-3.759 0.982
Nuclear grade (Ⅲ-Ⅳ / Ⅰ-Ⅱ) 2.300 0.494-10.722 0.275
pT stages (T3-4/ T1-2) 7.412 1.503-36.540 0.006 0.452
Vascular cancer embolism (Yes/No) 21.445 2.455-187.305 0.001 0.006
Lymph node metastasis (Yes/No) 10.386 1.241-86.938 0.008 0.499
Adrenal metastasis (Yes/No) 3.380 0.392-29.172 0.334
pRCC (Type 1 / Type 2) 0.863 0.331-2.674 0.132 0.493

Table 5

Univariate analysis of prognosis in pRCC patients with high pT stage"

Items HR 95%CI P
Gender (male/female) 0.281 0.035-2.270 0.163
BMI (>24.9 / ≤24.9 kg/m2) 1.379 0.385-4.944 0.626
Tumor location (Left/Right) 1.359 0.361-5.113 0.649
Surgical method (Radical/Partial) 1.815 0.465-7.079 0.375
Nuclear grade (Ⅲ-Ⅳ / Ⅰ-Ⅱ) 1.009 0.242-4.205 0.990
Vascular cancer embolism (Yes/No) 35.011 0.015-82 945.630 0.058
Lymph node metastasis (Yes/No) 1.994 0.395-10.068 0.376
Adrenal metastasis (Yes/No) 1.931 0.230-16.217 0.575
1 Siegel RL , Miller KD , Jemal A . Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69 (1): 7- 34.
doi: 10.3322/caac.21551
2 Qu Y , Chen H , Gu W , et al. Age-dependent association between sex and renal cell carcinoma mortality: A population-based analysis[J]. Sci Rep, 2015, 5 (1): 9160.
doi: 10.1038/srep09160
3 Znaor A , Lortet-Tieulent J , Laversanne M , et al. International variations and trends in renal cell carcinoma incidence and mortality[J]. Eur Urol, 2015, 67 (3): 519- 530.
doi: 10.1016/j.eururo.2014.10.002
4 Akhtar M , Al-Bozom IA , Al Hussain T . Papillary renal cell carcinoma (PRCC): An update[J]. Adv Anat Pathol, 2019, 26 (2): 124- 132.
doi: 10.1097/PAP.0000000000000220
5 Mir MC , Derweesh I , Porpiglia F , et al. Partial nephrectomy versus radical nephrectomy for clinical T1b and T2 renal tumors: A systematic review and meta-analysis of comparative studies[J]. Eur Urol, 2017, 71 (4): 606- 617.
doi: 10.1016/j.eururo.2016.08.060
6 Mancilla-Jimenez R , Stanley RJ , Blath RA , et al. Papillary renal cell carcinoma a clinical, radiologic, and pathologic study of 34 cases[J]. Cancer, 1976, 38 (6): 2469- 2480.
doi: 10.1002/1097-0142(197612)38:6<2469::AID-CNCR2820380636>3.0.CO;2-R
7 Thoenes W , Störkel S , Rumpelt HJ . Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas): The basic cytological and histopathological elements and their use for diagnostics[J]. Pathol Res Pract, 1986, 181 (2): 125- 143.
doi: 10.1016/S0344-0338(86)80001-2
8 Delahunt B , Eble JN . Papillary renal cell carcinoma: A clinicopathologic and immunohistochemical study of 105 tumors[J]. Mod Pathol, 1997, 10 (6): 537- 544.
9 Aron M , Nguyen MM , Stein RJ , et al. Impact of gender in renal cell carcinoma: An analysis of the SEER database[J]. Eur Urol, 2008, 54 (1): 133- 140.
doi: 10.1016/j.eururo.2007.12.001
10 Hong B , Hou H , Chen L , et al. The clinicopathological features and prognosis in patients with papillary renal cell carcinoma: A multicenter retrospective study in Chinese population[J]. Front Oncol, 2021, 11, 753690.
doi: 10.3389/fonc.2021.753690
11 Bigot P , Bernhard JC , Gill IS , et al. The subclassification of papillary renal cell carcinoma does not affect oncological outcomes after nephron sparing surgery[J]. World J Urol, 2016, 34 (3): 347- 352.
doi: 10.1007/s00345-015-1634-0
12 洪保安, 侯惠民, 陈凌霄, 等. 乳头状肾细胞癌的临床病理特征及预后分析[J]. 中华泌尿外科杂志, 2020, 41 (12): 896- 900.
doi: 10.3760/cma.j.cn112330-20200502-00350
13 董樑, 黄吉炜, 奚倩雯, 等. 乳头状肾细胞癌的临床病理特征和预后分析[J]. 中华泌尿外科杂志, 2015, 36 (3): 183- 187.
14 Ha YS , Chung JW , Choi SH , et al. Clinical significance of subclassification of papillary renal cell carcinoma: Comparison of cli-nicopathologic parameters and oncologic outcomes between papillary histologic subtypes 1 and 2 using the Korean renal cell carcinoma database[J]. Clin Genitourin Cancer, 2017, 15 (2): e181- e186.
doi: 10.1016/j.clgc.2016.07.020
15 Pan H , Ye L , Zhu Q , et al. The effect of the papillary renal cell carcinoma subtype on oncological outcomes[J]. Sci Rep, 2020, 10 (1): 21073.
doi: 10.1038/s41598-020-78174-9
16 Sukov WR , Lohse CM , Leibovich BC , et al. Clinical and pathological features associated with prognosis in patients with papillary renal cell carcinoma[J]. J Urol, 2012, 187 (1): 54- 59.
doi: 10.1016/j.juro.2011.09.053
17 Ku JH , Moon KC , Kwak C , et al. Is there a role of the histologic subtypes of papillary renal cell carcinoma as a prognostic factor?[J]. Jpn J Clin Oncol, 2009, 39 (10): 664- 670.
doi: 10.1093/jjco/hyp075
18 黄健. 中国泌尿外科和男科疾病诊断治疗指南(2019版)[M]. 北京: 科学出版社, 2020: 6- 8.
19 Fernandes DS , Lopes JM . Pathology, therapy and prognosis of papillary renal carcinoma[J]. Future Oncol, 2015, 11 (1): 121- 132.
doi: 10.2217/fon.14.133
20 Begg CB , Cramer LD , Hoskins WJ . Impact of hospital volume on operative mortality for major cancer surgery[J]. JAMA, 1998, 280 (20): 1747- 1751.
doi: 10.1001/jama.280.20.1747
[1] Junyong OU,Kunming NI,Lulin MA,Guoliang WANG,Ye YAN,Bin YANG,Gengwu LI,Haodong SONG,Min LU,Jianfei YE,Shudong ZHANG. Prognostic factors of patients with muscle invasive bladder cancer with intermediate-to-high risk prostate cancer [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 582-588.
[2] Shuai LIU,Lei LIU,Zhuo LIU,Fan ZHANG,Lulin MA,Xiaojun TIAN,Xiaofei HOU,Guoliang WANG,Lei ZHAO,Shudong ZHANG. Clinical treatment and prognosis of adrenocortical carcinoma with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 624-630.
[3] Le YU,Shaohui DENG,Fan ZHANG,Ye YAN,Jianfei YE,Shudong ZHANG. Clinicopathological characteristics and prognosis of multilocular cystic renal neoplasm of low malignant potential [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 661-666.
[4] Zezhen ZHOU,Shaohui DENG,Ye YAN,Fan ZHANG,Yichang HAO,Liyuan GE,Hongxian ZHANG,Guoliang WANG,Shudong ZHANG. Predicting the 3-year tumor-specific survival in patients with T3a non-metastatic renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 673-679.
[5] Yangyi FANG,Qiang LI,Zhigao HUANG,Min LU,Kai HONG,Shudong ZHANG. Well-differentiated papillary mesothelial tumour of the tunica vaginalis: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 741-744.
[6] Yuanyuan ZENG,Yun XIE,Daonan CHEN,Ruilan WANG. Related factors of euthyroid sick syndrome in patients with sepsis [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 526-532.
[7] Jian-bin LI,Meng-na LYU,Qiang CHI,Yi-lin PENG,Peng-cheng LIU,Rui WU. Early prediction of severe COVID-19 in patients with Sjögren’s syndrome [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1007-1012.
[8] Huan-rui LIU,Xiang PENG,Sen-lin LI,Xin GOU. Risk modeling based on HER-2 related genes for bladder cancer survival prognosis assessment [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 793-801.
[9] Zi-xuan XUE,Shi-ying TANG,Min QIU,Cheng LIU,Xiao-jun TIAN,Min LU,Jing-han DONG,Lu-lin MA,Shu-dong ZHANG. Clinicopathologic features and prognosis of young renal tumors with tumor thrombus [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 802-811.
[10] Han LU,Jian-yun ZHANG,Rong YANG,Le XU,Qing-xiang LI,Yu-xing GUO,Chuan-bin GUO. Clinical factors affecting the prognosis of lower gingival squamous cell carcinoma [J]. Journal of Peking University (Health Sciences), 2023, 55(4): 702-707.
[11] Yun-fei SHI,Hao-jie WANG,Wei-ping LIU,Lan MI,Meng-ping LONG,Yan-fei LIU,Yu-mei LAI,Li-xin ZHOU,Xin-ting DIAO,Xiang-hong LI. Analysis of clinicopathological and molecular abnormalities of angioimmunoblastic T-cell lymphoma [J]. Journal of Peking University (Health Sciences), 2023, 55(3): 521-529.
[12] Li-jia MA,Pan-pan HU,Xiao-guang LIU. Spinal metastases combined with leptomeningeal metastasis: A case report [J]. Journal of Peking University (Health Sciences), 2023, 55(3): 563-566.
[13] Xiao-juan ZHU,Hong ZHANG,Shuang ZHANG,Dong LI,Xin LI,Ling XU,Ting LI. Clinicopathological features and prognosis of breast cancer with human epidermal growth factor receptor 2 low expression [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 243-253.
[14] Yu-mei LAI,Zhong-wu LI,Huan LI,Yan WU,Yun-fei SHI,Li-xin ZHOU,Yu-tong LOU,Chuan-liang CUI. Clinicopathological features and prognosis of anorectal melanoma: A report of 68 cases [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 262-269.
[15] Qi SHEN,Yi-xiao LIU,Qun HE. Mucinous tubular and spindle cell carcinoma of kidney: Clinicopathology and prognosis [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 276-282.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd